fbpx
June 5, 2022

First-Line Treatment in Newly Diagnosed Multiple Myeloma First-Line Treatment in Newly Diagnosed Multiple Myeloma

New results from a trial in patients with newly diagnosed multiple myeloma offer some answers to questions about which treatment route to choose. The trial, known […]
June 5, 2022

International Trial Finds Best Regimen for Ewing Sarcoma International Trial Finds Best Regimen for Ewing Sarcoma

High-dose ifosfamide has shown superior survival benefit over three other chemotherapy regimens for patients with recurring or refractory primary Ewing sarcoma (RR-ES) in the practice-changing rEECur […]
June 5, 2022

Panitumumab Beats Bevacizumab in Left-Sided mCRC Panitumumab Beats Bevacizumab in Left-Sided mCRC

A suspicion from retrospective data has now been confirmed by a prospective clinical trial: adding panitumumab (Vectibix) to standard chemotherapy in left-sided RAS wild-type metastatic colorectal […]
June 5, 2022

Weekly Dulaglutide Promising in Youth With Type 2 Diabetes Weekly Dulaglutide Promising in Youth With Type 2 Diabetes

Another glucagon-like peptide-1 (GLP1) agonist, dulaglutide (Trulicity, Lilly), is poised to be a new option for glycemic control in youth ages 10 to 18 with type […]
June 5, 2022

‘Great Optimism’ Over Complete Responses in dMMR Rectal Cancer ‘Great Optimism’ Over Complete Responses in dMMR Rectal Cancer

Patients with locally advanced rectal cancer and tumors with deficient mismatch repair (dMMR) have shown a remarkable response to treatment with the programmed cell death-1 (PD-1) […]
June 4, 2022

Tirzepatide Powers ‘Unprecedented’ Weight Loss in SURMOUNT-1 Tirzepatide Powers ‘Unprecedented’ Weight Loss in SURMOUNT-1

Treatment of people with obesity but no diabetes with the dual incretin agonist tirzepatide safely produced “unprecedented” levels of weight loss in the vast majority of […]
June 4, 2022

Tirzepatide Powers ‘Unprecedented’ Weight Loss in Obesity Trial Tirzepatide Powers ‘Unprecedented’ Weight Loss in Obesity Trial

Dr Ania M. Jastreboff Treatment of people with obesity but no diabetes with the dual incretin agonist tirzepatide safely produced “unprecedented” levels of weight loss in […]
June 4, 2022

Bionic Pancreas: Closer to Fully Automated Insulin Delivery? Bionic Pancreas: Closer to Fully Automated Insulin Delivery?

The investigational insulin-only iLet Bionic Pancreas (Beta Bionics) reduced A1c without increasing hypoglycemia in adults and children with type 1 diabetes with greater automation than currently […]
June 4, 2022

ctDNA Identifies Colon Cancer Patients Who Can Skip Chemo ctDNA Identifies Colon Cancer Patients Who Can Skip Chemo

A “liquid biopsy” that detects circulating tumor DNA (ctDNA) after surgery for stage 2 colon cancer helps identify patients who are most likely to benefit from […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792793794795
Next page
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0